兔体内可生物降解纳米球包裹的口服齐多夫定的药代动力学
Pharmacokinetics of oral zidovudine entrapped in biodegradable nanospheres in rabbits.
作者信息
Callender D P, Jayaprakash N, Bell A, Petraitis V, Petraitiene R, Candelario M, Schaufele R, Dunn J M, Sei S, Walsh T J, Balis F M
机构信息
Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.
出版信息
Antimicrob Agents Chemother. 1999 Apr;43(4):972-4. doi: 10.1128/AAC.43.4.972.
Abstract
The pharmacokinetic profile of oral zidovudine entrapped in a 50:50 polyactide-coglycolide matrix (nanospheres) was compared to those of standard oral and parenteral zidovudine formulations in rabbits. The bioavailability of zidovudine nanospheres at 50 mg/kg of body weight was 76%, and this dose achieved prolonged exposure to zidovudine compared to standard formulations without an increase in the drug's peak concentration.
摘要
将包裹于50:50聚丙交酯-乙交酯基质（纳米球）中的口服齐多夫定的药代动力学特征，与兔体内标准口服及肠胃外齐多夫定制剂的药代动力学特征进行了比较。体重50 mg/kg时，齐多夫定纳米球的生物利用度为76%，与标准制剂相比，该剂量实现了对齐多夫定的延长暴露，且未增加药物的峰值浓度。
相似文献
1
Pharmacokinetics of oral zidovudine entrapped in biodegradable nanospheres in rabbits.
Antimicrob Agents Chemother. 1999 Apr;43(4):972-4. doi: 10.1128/AAC.43.4.972.
2
Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.
Pediatr Infect Dis J. 2014 May;33(5):495-8. doi: 10.1097/INF.0000000000000143.
3
Time-dependent pharmacokinetic interaction between zidovudine and rifampicin following oral administration at 10.00 and 22.00 hours.
Drug Metabol Drug Interact. 2001;18(2):123-34. doi: 10.1515/dmdi.2001.18.2.123.
4
Pharmacokinetics of zidovudine following intravenous bolus administration of a novel niosome preparation devoid of cholesterol.
Arzneimittelforschung. 2001 Nov;51(11):924-30. doi: 10.1055/s-0031-1300139.
5
Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers.
J Med Assoc Thai. 2006 Sep;89 Suppl 3:S79-85.
6
Tissue distribution, pharmacokinetics and stability studies of zidovudine delivered by niosomes and proniosomes.
J Biomed Nanotechnol. 2010 Feb;6(1):43-51. doi: 10.1166/jbn.2010.1101.
7
Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.
Antimicrob Agents Chemother. 1997 Nov;41(11):2428-32. doi: 10.1128/AAC.41.11.2428.
8
Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study.
Clin Ther. 2008 May;30(5):902-8. doi: 10.1016/j.clinthera.2008.05.003.
9
Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children.
J Antimicrob Chemother. 2004 Dec;54(6):1152-4. doi: 10.1093/jac/dkh490. Epub 2004 Nov 10.
10
Pharmacokinetics of oral zidovudine administered during labour: a preliminary study.
HIV Med. 2007 Oct;8(7):451-6. doi: 10.1111/j.1468-1293.2007.00495.x.
引用本文的文献
1
Improved Safety, Bioavailability and Pharmacokinetics of Zidovudine through Lactoferrin Nanoparticles during Oral Administration in Rats.
PLoS One. 2015 Oct 13;10(10):e0140399. doi: 10.1371/journal.pone.0140399. eCollection 2015.
2
Composite alginate hydrogel microparticulate delivery system of zidovudine hydrochloride based on counter ion induced aggregation.
Int J Appl Basic Med Res. 2014 Sep;4(Suppl 1):S31-6. doi: 10.4103/2229-516X.140728.
3
Alginate nanoparticles as a promising adjuvant and vaccine delivery system.
Indian J Pharm Sci. 2013 Jul;75(4):442-9. doi: 10.4103/0250-474X.119829.
4
Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics.
Pharm Res. 2001 Nov;18(11):1521-7. doi: 10.1023/a:1013018111829.
本文引用的文献
1
In vivo evaluation of zidovudine (AZT)-loaded ethylcellulose microspheres after oral administration in beagle dogs.
J Pharm Sci. 1997 May;86(5):554-9. doi: 10.1021/js960461b.
2
Clinical pharmacokinetics of zidovudine. An update.
Clin Pharmacokinet. 1996 Apr;30(4):251-62. doi: 10.2165/00003088-199630040-00001.
3
The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites.
AIDS. 1996 Oct;10(12):1361-7. doi: 10.1097/00002030-199610000-00008.
4
Preparation of biodegradable microcapsules containing zidovudine (AZT) using solvent evaporation technique.
J Microencapsul. 1996 May-Jun;13(3):257-67. doi: 10.3109/02652049609026014.
5
Preparation and evaluation of sustained release AZT-loaded microspheres: optimization of the release characteristics using response surface methodology.
J Pharm Sci. 1996 Feb;85(2):144-9. doi: 10.1021/js950353+.
6
Noncompartmental determination of the steady-state volume of distribution for any mode of administration.
J Pharm Sci. 1982 Mar;71(3):372-3. doi: 10.1002/jps.2600710332.
7
Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits.
Lab Anim Sci. 1988 Aug;38(4):467-71.
8
Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection.
J Pediatr. 1989 May;114(5):880-4. doi: 10.1016/s0022-3476(89)80158-1.
9
The pharmacokinetics of zidovudine administered by continuous infusion in children.
Ann Intern Med. 1989 Feb 15;110(4):279-85. doi: 10.7326/0003-4819-110-4-279.
Zotero 插件